Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on May 5, 2025
FibroGen to Report First Quarter 2025 Financial Results
GlobeNewswire
·
May 5, 2025
SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time …
Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights
GlobeNewswire
·
May 5, 2025
Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients that are currently uncontrolled on a …
Tactile Systems Technology, Inc. Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 5, 2025
MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the …
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates
GlobeNewswire
·
May 5, 2025
Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented preclinical data supporting potential best-in-class profile of ORIC-944 in combination with AR …
uniQure to Announce First Quarter 2025 Financial Results
GlobeNewswire
·
May 5, 2025
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report first quarter 2025 financial …
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
May 5, 2025
- Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q’25 - - Reported positive data from the Company’s ongoing Phase 2a trial of lead …
Inspire Medical Systems, Inc. Announces First Quarter 2025 Financial Results and Updates 2025 Outlook
GlobeNewswire
·
May 5, 2025
Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company …
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease
GlobeNewswire
·
May 5, 2025
HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). Biopsies taken during screening demonstrate the presence …
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
GlobeNewswire
·
May 5, 2025
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q1 2025 financial …
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
GlobeNewswire
·
May 5, 2025
REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT …
Solésence Reports Record First Quarter 2025 Financial Results
GlobeNewswire
·
May 5, 2025
First quarter revenue increased 48% to a record $14.6 million ROMEOVILLE, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today …
Xenon to Report Q1 2025 Financial Results on May 12, 2025
GlobeNewswire
·
May 5, 2025
VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for …
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 5, 2025
– $20.0 million in Revuforj® (revumenib) net revenue in first full quarter of launch – – $13.6 million in Niktimvo™ (axatilimab-csfr) net revenue (reported by Incyte) in first partial quarter of launch – – Submitted sNDA for revumenib in R/R mNPM1 AML – – …
DrEO Clinic Named Best Hair Transplant Clinic in Mexico for 2025, Leading the Way in Affordable Medical Tourism
GlobeNewswire
·
May 5, 2025
Mexico City, Mexico, May 05, 2025 (GLOBE NEWSWIRE) -- DrEO Clinic has been recognized as the best hair transplant clinic in Mexico for 2025, reinforcing its position at the forefront of hair restoration excellence. The announcement follows endorsements …
Robert Olsen Receives Individual Achievement Award from the Healthcare Financial Management Association
GlobeNewswire
·
May 5, 2025
NASHVILLE, Tenn., May 05, 2025 (GLOBE NEWSWIRE) -- The Healthcare Financial Management Association (HFMA) today presented Robert Olsen with the 2025 Frederick C. Morgan Individual Achievement Award, honoring career-long contributions to HFMA and to the …
Prostate Cancer Types Market Set for Robust Growth Through 2034, Driven by Advances in Targeted Therapies and Biomarker | DelveInsight
GlobeNewswire
·
May 5, 2025
New York, USA, May 05, 2025 (GLOBE NEWSWIRE) -- Prostate Cancer Types Market Set for Robust Growth Through 2034, Driven by Advances in Targeted Therapies and Biomarker | DelveInsight The prostate cancer market is expected to witness significant growth …
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
GlobeNewswire
·
May 5, 2025
ZURICH, SWITZERLAND, May 05, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ: VACH, "Voyager"), announced today a co- …
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab
GlobeNewswire
·
May 5, 2025
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab Lusvertikimab well tolerated over the 24-week additional treatment period. Oral presentation at DDW 2025 of clinical data from …
OSE Immunotherapeutics annonce que plus de 90% des patients répondeurs ont maintenu une rémission symptomatique pendant la période d’extension sous Lusvertikimab
GlobeNewswire
·
May 5, 2025
OSE Immunotherapeutics annonce que plus de 90 % des patients répondeurs ont maintenu une rémission symptomatique pendant la période d’extension sous Lusvertikimab Bonne tolérance de Lusvertikimab pendant les 24 semaines supplémentaires de traitement. …
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
GlobeNewswire
·
May 5, 2025
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell …